Abiopharma

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

New Form 6-K - Haleon plc Filed: 2025-06-17 AccNo: 0001654954-25-007079 Size: 51 KB

New Form 6-K - Haleon plc Filed: 2025-06-17 AccNo: 0001654954-25-007077 Size: 36 KB

New Form 6-K - GSK plc Filed: 2025-06-17 AccNo: 0001654954-25-007075 Size: 2 MB

New Form SC 14D9/A - Regulus Therapeutics Inc. Filed: 2025-06-17 AccNo: 0001104659-25-060054 Size: 43 KB

New Form SC TO-T/A - Regulus Therapeutics Inc. Filed: 2025-06-17 AccNo: 0001104659-25-060052 Size: 24 KB

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

New Form 8-K - Vivani Medical, Inc. Filed: 2025-06-17 AccNo: 0001753926-25-000966 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form SC 14D9/A - Inozyme Pharma, Inc. Filed: 2025-06-17 AccNo: 0001193125-25-141714 Size: 20 KB

New Form 8-K - Immuneering Corp Filed: 2025-06-17 AccNo: 0001790340-25-000077 Size: 151 KB Item 8.01: Other Events

New Form 6-K - Regencell Bioscience Holdings Ltd Filed: 2025-06-17 AccNo: 0001213900-25-054936 Size: 25 KB

New Form SC TO-T - Blueprint Medicines Corp Filed: 2025-06-17 AccNo: 0001193125-25-141704 Size: 1 MB

New Form 8-K - AYTU BIOPHARMA, INC Filed: 2025-06-17 AccNo: 0001437749-25-020579 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 6-K - Innate Pharma SA Filed: 2025-06-17 AccNo: 0001598599-25-000060 Size: 23 KB

New Form DEF 14A - Nexalin Technology, Inc. Filed: 2025-06-17 AccNo: 0001829126-25-004535 Size: 1 MB